NCT05811442

Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

A Phase IIa, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 50561 in Patients With Mild or Moderate Alzheimer's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Beijing Joekai Biotechnology LLC · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's disease.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	50561 high dose	study drug
DRUG	50561 low dose	study drug
DRUG	Placebo	Non-active study drug

Timeline

• Start date: 2023-04-18
• Primary completion: 2025-08-22
• Completion: 2025-09-11
• First posted: 2023-04-13
• Last updated: 2025-09-18

Locations

12 sites across 1 country: China